Nature Communications (Jul 2019)
Sequential LASER ART and CRISPR Treatments Eliminate HIV-1 in a Subset of Infected Humanized Mice
- Prasanta K. Dash,
- Rafal Kaminski,
- Ramona Bella,
- Hang Su,
- Saumi Mathews,
- Taha M. Ahooyi,
- Chen Chen,
- Pietro Mancuso,
- Rahsan Sariyer,
- Pasquale Ferrante,
- Martina Donadoni,
- Jake A. Robinson,
- Brady Sillman,
- Zhiyi Lin,
- James R. Hilaire,
- Mary Banoub,
- Monalisha Elango,
- Nagsen Gautam,
- R. Lee Mosley,
- Larisa Y. Poluektova,
- JoEllyn McMillan,
- Aditya N. Bade,
- Santhi Gorantla,
- Ilker K. Sariyer,
- Tricia H. Burdo,
- Won-Bin Young,
- Shohreh Amini,
- Jennifer Gordon,
- Jeffrey M. Jacobson,
- Benson Edagwa,
- Kamel Khalili,
- Howard E. Gendelman
Affiliations
- Prasanta K. Dash
- Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center
- Rafal Kaminski
- Department of Neuroscience, Lewis Katz School of Medicine at Temple University
- Ramona Bella
- Department of Neuroscience, Lewis Katz School of Medicine at Temple University
- Hang Su
- Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center
- Saumi Mathews
- Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center
- Taha M. Ahooyi
- Department of Neuroscience, Lewis Katz School of Medicine at Temple University
- Chen Chen
- Department of Neuroscience, Lewis Katz School of Medicine at Temple University
- Pietro Mancuso
- Department of Neuroscience, Lewis Katz School of Medicine at Temple University
- Rahsan Sariyer
- Department of Neuroscience, Lewis Katz School of Medicine at Temple University
- Pasquale Ferrante
- Department of Neuroscience, Lewis Katz School of Medicine at Temple University
- Martina Donadoni
- Department of Neuroscience, Lewis Katz School of Medicine at Temple University
- Jake A. Robinson
- Department of Neuroscience, Lewis Katz School of Medicine at Temple University
- Brady Sillman
- Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center
- Zhiyi Lin
- Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center
- James R. Hilaire
- Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center
- Mary Banoub
- Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center
- Monalisha Elango
- Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center
- Nagsen Gautam
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center
- R. Lee Mosley
- Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center
- Larisa Y. Poluektova
- Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center
- JoEllyn McMillan
- Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center
- Aditya N. Bade
- Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center
- Santhi Gorantla
- Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center
- Ilker K. Sariyer
- Department of Neuroscience, Lewis Katz School of Medicine at Temple University
- Tricia H. Burdo
- Department of Neuroscience, Lewis Katz School of Medicine at Temple University
- Won-Bin Young
- Department of Neuroscience, Lewis Katz School of Medicine at Temple University
- Shohreh Amini
- Department of Neuroscience, Lewis Katz School of Medicine at Temple University
- Jennifer Gordon
- Department of Neuroscience, Lewis Katz School of Medicine at Temple University
- Jeffrey M. Jacobson
- Department of Neuroscience, Lewis Katz School of Medicine at Temple University
- Benson Edagwa
- Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center
- Kamel Khalili
- Department of Neuroscience, Lewis Katz School of Medicine at Temple University
- Howard E. Gendelman
- Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center
- DOI
- https://doi.org/10.1038/s41467-019-10366-y
- Journal volume & issue
-
Vol. 10,
no. 1
pp. 1 – 20
Abstract
Here, the authors show that sequential treatment with long-acting slow-effective release ART and AAV9- based delivery of CRISPR-Cas9 results in undetectable levels of virus and integrated DNA in a subset of humanized HIV-1 infected mice. This proof-of-concept study suggests that HIV-1 elimination is possible.
